ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 950

In a Two-Year Double-Blind Randomized Controlled Multicenter Study, Chondroitin Sulfate Was Significantly Superior to Celecoxib at Reducing Cartilage Loss with Similar Efficacy at Reducing Disease Symptoms in Knee Osteoarthritis Patients

Jean-Pierre Pelletier1, Jean Pierre Raynauld2, André Beaulieu3, Louis Bessette4, Frédéric Morin5, Artur J Fernandes6, François Abram7, Marc Dorais8 and Johanne Martel-Pelletier9, 1Rheumatology, Institut de recherche en rhumatologie de Montréal (IRRM), Montréal, QC, Canada, 2Osteoarthritis Research Unit, CRCHUM, Montreal, Montreal, QC, Canada, 3Centre de rhumatologie St-Louis, St. Louis, QC, Canada, 4Groupe de Recherche en Rhumatologie et Maladies Osseuses, Quebec, Quebec, QC, Canada, 5Centre de Recherche Musculo-squelettique, Trois-Rivières, Trois-Rivières, QC, Canada, 6Centre de Recherche Musculo-squelettique, Trois-Rivières, 6Rheumatology Division, Sherbrooke, Sherbrooke, QC, Canada, 7Medical Imaging Research & Development, ArthroLab Inc, Montreal, QC, Canada, 8StatSciences Inc., Montreal, Canada, Montreal, QC, Canada, 9Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM),, Montreal, QC, Canada

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Clinical, Knee, MRI, OA and chondroitin

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2015

Session Title: Osteoarthritis - Clinical Aspects: Treatments and Epidemiology

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: In osteoarthritis (OA) treatment, although chondroitin sulfate (CS) was found in a number of studies using radiography to have a structure modifying effect, to date the question is still under debate. A clinical study using quantitative magnetic resonance imaging (qMRI) is therefore of the utmost importance.

The present study has the objective to explore, as the first aim, in a two-year randomized, controlled double-blind clinical study (RCT) using qMRI, the disease modifying effect of CS treatment versus celecoxib (CE) on cartilage volume loss (CVL) in knee OA. The second aim was to investigate and compare the effect of CS and celecoxib on symptoms.

 

Methods: Symptomatic primary knee OA patients according to ACR criteria with Kellgren-Lawrence grades 2-3 and synovitis were included and treated with CS (1200 mg a day) or CE (200 mg once daily) for 24 months. Patients at high risk for cardiovascular and/or gastrointestinal disease were not included. MRI was performed at baseline, 12 and 24 months. CVL, bone marrow lesion (BML) size, and synovial membrane thickness were evaluated using qMRI, and presence of joint swelling and effusion clinically evaluated. Clinical symptoms were also assessed by validated questionnaires. Statistical analyses were done on the intention-to-treat (ITT) population (n=194 patients), per protocol set (n= 195) and the according-to-protocol completer population (n=120) using Student’s t-test, Wilcoxon Mann-Whitney test, and ANCOVA.

Results: In the ITT population, OA patients treated with CS (n=97) had a reduction in CVL at 12 months (p=0.017) and 24 months in the medial tibiofemoral compartment (p=0.013) and global knee at 12 (p= 0.034) and 24 months (p=0.054) compared to CE (n=97). No difference in change in synovial thickness or BML size between the two treatment groups was observed over time. A marked reduction in the incidence of patients with joint swelling plus effusion was observed in both the CS (51%, 59 vs 6 patients) and celecoxib (39%, 55 vs 11 patients) groups from baseline to 24 months, without differences between treatments. Both therapeutic groups experienced a reduction in disease symptoms (WOMAC total, pain, and function, and VAS pain) over time: reduction in VAS pain at 24 months for CS and celecoxib was 48% and 55% respectively, and for WOMAC pain 43% and 54%. The overall daily consumption of rescue analgesic (acetaminophen) was not different between CS and celecoxib (584 vs 472 mg/day) groups. The incidence of adverse events was similar in both treatment groups.

Conclusion: This trial demonstrated, for the first time, the superiority of CS over CE at reducing the long term progression of knee OA structural changes. Moreover, both drugs were found equally effective at reducing the symptoms of OA. These findings have important implications regarding the usefulness of CS for long term management of knee OA and its impact on disease outcome.


Disclosure: J. P. Pelletier, None; J. P. Raynauld, None; A. Beaulieu, None; L. Bessette, None; F. Morin, None; A. J. Fernandes, None; F. Abram, None; M. Dorais, None; J. Martel-Pelletier, None.

To cite this abstract in AMA style:

Pelletier JP, Raynauld JP, Beaulieu A, Bessette L, Morin F, Fernandes AJ, Abram F, Dorais M, Martel-Pelletier J. In a Two-Year Double-Blind Randomized Controlled Multicenter Study, Chondroitin Sulfate Was Significantly Superior to Celecoxib at Reducing Cartilage Loss with Similar Efficacy at Reducing Disease Symptoms in Knee Osteoarthritis Patients [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/in-a-two-year-double-blind-randomized-controlled-multicenter-study-chondroitin-sulfate-was-significantly-superior-to-celecoxib-at-reducing-cartilage-loss-with-similar-efficacy-at-reducing-disease-sym/. Accessed June 25, 2022.
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/in-a-two-year-double-blind-randomized-controlled-multicenter-study-chondroitin-sulfate-was-significantly-superior-to-celecoxib-at-reducing-cartilage-loss-with-similar-efficacy-at-reducing-disease-sym/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies